Key points
- FY26 Underlying EBITDA of $53.4m, down 19.5% vs FY25
- Australian market share stabilized in 2HFY26
- Strong growth in Asian markets, with Singapore and Kuala Lumpur leading
- Strategic initiatives and cost optimizations underway to improve margins
- FY27 outlook positive with new strategy and growth platforms in place
Full summary
Monash IVF Group's FY26 results reveal a challenging year with a decline in revenue and profitability. The Australian market showed signs of stabilization in the second half of the year, while the Asian market continued to grow strongly, particularly in Singapore and Kuala Lumpur. The company is focusing on productivity improvements and strategic initiatives to enhance margins. The outlook for FY27 is positive, with a new three-year strategy in place and growth platforms being strengthened. The company is also investing in capital to unlock growth capacity and improve patient outcomes.
Outlook
The company expects to see improved margins and revenue growth in FY27, driven by strategic initiatives and cost optimizations. The outlook for the Australian market is stabilizing, with potential for growth as economic conditions stabilize.